Product Description: Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an Kd value of 1.5 nM. Nirsevimab can be used for RSV research[1][2][3].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]Griffin MP, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425. /[2]Griffin MP, et al. Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e01714-16. /[3]Cabán M, et al. Cross-protective antibodies against common endemic respiratory viruses. Nat Commun. 2023 Feb 13;14(1):798.
CAS Number: 1989556-22-0
Molecular Weight: N/A
Compound Purity: 95.0
Research Area: Infection
Solubility: 10 mM in DMSO
Target: RSV
English
Deutsch
